FDA Approves GLATIRAMER ACETATE — AJENAT PHARMACEUTICALS LLC

# FDA Approves Generic Glatiramer Acetate for Ajenat Pharmaceuticals Ajenat Pharmaceuticals LLC has received FDA approval for its generic glatiramer acetate injection (ANDA213382), a subcutaneous treatment for multiple sclerosis that could intensify competition in the immunosuppressant market and put downward pressure on pricing for the established therapeutic category. The approval expands the generic alternatives available to patients and payers, potentially reshaping market share among MS drug manufacturers.